Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 16/20 | 0.69 |
| ▸ | MAOA | P21397 | 12/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14382308 | 0.96 | MAOB (0.65) | MAOBMAOAHRH3 | |
| SCHEMBL6825904 | 0.94 | MAOB (0.67) | MAOBMAOAHRH3 | |
| SCHEMBL21300548 | 0.92 | MAOB (0.64) | MAOBMAOAHRH3 | |
| SCHEMBL8272631 | 0.91 | MAOB (0.69) | MAOBMAOAHRH3 | |
| SCHEMBL1377016 | 0.88 | MAOB (0.69) | MAOBMAOAHRH3 | |
| SCHEMBL27974960 | 0.88 | MAOB (0.66) | MAOBMAOAHRH3 | |
| SCHEMBL6825249 | 0.88 | MAOB (0.66) | MAOBMAOAHRH3 | |
| SCHEMBL1030417 | 0.87 | MAOB (0.64) | MAOBMAOAHRH3 | |
| SCHEMBL14287611 | 0.86 | MAOB (0.69) | MAOBMAOAHRH3 | |
| SCHEMBL17040461 | 0.85 | MAOB (0.63) | MAOBMAOAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327342-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-10-03 | — | — | US | disclosed |
| EP-4431157-A2 | 1-[[(3S)-3-METHYL-6-(4(4,4-TRIFLUOROBUTOXY)-3,4-DIHYDRONAPHTHALEN-2YL]METHYL]AZETIDINE-3-CARBOXYLIC ACID HAVING S1P5 RECEPTOR AGONIST ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | ONO Pharmaceutical Co., Ltd. (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12049445-B2 | Compounds having S1P5 receptor agonistic activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-30 | — | — | US | disclosed |
| CN-111757869-B | Compounds having S1P5 receptor agonistic activity | 小野药品工业株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20220055986-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-24 | — | — | US | disclosed |
| US-11198672-B2 | Compounds having S1P5 receptor agonistic activity | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-12-14 | — | — | US | disclosed |
| US-20210087141-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3757091-A1 | COMPOUND HAVING S1P5 RECEPTOR AGONIST ACTIVITY | ONO Pharmaceutical Co., Ltd. (JP) | 2020-12-30 | — | — | EP | disclosed |
| CN-111757869-A | Compounds having S1P5 receptor agonistic activity | 小野药品工业株式会社 | 2020-10-09 | — | — | CN | disclosed |
| US-20170129855-A1 | TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20120258513-A1 | Selective Neuronal Nitric Oxide Synthase Inhibitors | NORTHWESTERN UNIVERSITY | 2012-10-11 | — | — | US | disclosed |
| EP-2502918-A1 | Pyridizinone Derivatives | Cephalon, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2492263-A1 | Pyridizinone Derivatives | Cephalon, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2008013838-A2 | PYRIDIZINONE DERIVATIVES | CEPHALON, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-0524517-B1 | Substituted 3,4-dihydronaphthalenes, medicament containing them and process for their preparation | GRUENENTHAL GMBH (DE) | 1995-06-21 | — | — | EP | disclosed |
| US-5254731-A | Enzyme inhibitors; leukotriene disorders | GRUENENTHAL GMBH (DE) | 1993-10-19 | — | — | US | disclosed |
| EP-0524517-A1 | Substituted 3,4-dihydronaphthalenes, medicament containing them and process for their preparation | Grünenthal GmbH (DE) | 1993-01-27 | — | — | EP | disclosed |
| EP-0284359-B1 | 1,4-DISUBSTITUTED PIPERAZINE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1992-01-08 | — | — | EP | disclosed |
| US-4880809-A | HYPOTENSIVE AGENTS, AMIDE DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| US-4016281-A | Tetralone and indanone compounds | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258513-A1 | Selective Neuronal Nitric Oxide Synthase Inhibitors | NOS2, NOS1, NOS3 | MAOB 81/4885MAOA 92/4885HRH3 2367/4885 |
| US-12049445-B2 | Compounds having S1P5 receptor agonistic activity | S1PR5, S1PR1, S1PR4 | MAOB 2121/4885MAOA 2474/4885HRH3 866/4885 |
| US-20240327342-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | MAOB 2121/4885MAOA 2474/4885HRH3 866/4885 |
| US-11198672-B2 | Compounds having S1P5 receptor agonistic activity | S1PR5, S1PR1, S1PR4 | MAOB 2121/4885MAOA 2474/4885HRH3 866/4885 |
| US-20210087141-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | MAOB 2121/4885MAOA 2474/4885HRH3 866/4885 |
| US-20220055986-A1 | COMPOUNDS HAVING S1P5 RECEPTOR AGONISTIC ACTIVITY | S1PR5, S1PR1, S1PR4 | MAOB 2121/4885MAOA 2474/4885HRH3 866/4885 |
| US-20170129855-A1 | TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GPER1, ESR2, ESR1 | MAOB 2151/4885MAOA 2115/4885HRH3 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.